Anixa Reports Q3 Loss of $0.08/Share, Zero Revenue; Maintains Over 12-Month Cash Runway
Summary
Anixa Biosciences reported its third-quarter results, showing no revenue and a net loss of $0.08 per share for the period ending January 31, 2026. While the company remains pre-revenue, which is expected for a clinical-stage biotech, it demonstrated an improvement in both operational and net losses compared to the prior year. Crucially, the company confirmed it has a cash runway exceeding 12 months, supported by recent equity financing, providing stability for its ongoing cancer vaccine and CAR-T programs. This financial update is significant for investors assessing the company's burn rate and ability to fund its development pipeline following the positive Phase 1 breast cancer vaccine results previously announced.
At the time of this announcement, ANIX was trading at $2.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $99.5M. The 52-week trading range was $2.33 to $5.46. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.